Clinical Trial Update: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy [Phase 3]

View source ↗

Summary

This Phase 3 unblinded trial evaluated TAK-438 (20 mg) for preventing recurrence of gastric or duodenal ulcers in patients on long-term low-dose aspirin therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Ulcer

Drugs mentioned

• TAK-438 (vonoprazan)

Snippet

Sponsor: Takeda | Conditions: Gastric Ulcer, Duodenal Ulcer | Phase 3 | Status: COMPLETED